ReviewHealth science reports2026
Molecular Mechanisms of Resistance and Treatment Efficacy of Delamanid Against
Review in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Molecular Mechanisms of Resistance and Treatment Efficacy of Delamanid AgainstHealth science reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Tuberculosis (TB) remains a major global health problem, and treatment progress is increasingly threatened by rising multidrug-resistant tuberculosis (MDR-TB). Delamanid (DLM), a nitroimidazole drug, has shown good efficacy and safety against both drug-susceptible and drug-resistant Methods: A comprehensive literature search was performed using WHO publications and major scientific databases, including PubMed, Web of Science, Embase, Scopus, and the Cochrane Library. Studies published through 2024 and early 2025 on DLM resistance, mechanisms of action, DST, pharmacokinetics, safety, and treatment outcomes were included. Structural analyses of key proteins involved in DLM activation were carried out using crystal structures and AlphaFold models. Results: Recent research identified multiple mutations in the F420-dependent activation pathway, particularly in Conclusion: DLM is an important and effective component of MDR-/XDR-TB treatment. A clearer understanding of its resistance mechanisms, pharmacological properties, and clinical outcomes can support better regimen design and help prevent the development of further resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.